Karyopharm Therapeutics (KPTI) Payables (2016 - 2025)
Historic Payables for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $4.0 million.
- Karyopharm Therapeutics' Payables fell 2161.74% to $4.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 million, marking a year-over-year decrease of 2161.74%. This contributed to the annual value of $4.0 million for FY2025, which is 2161.74% down from last year.
- Per Karyopharm Therapeutics' latest filing, its Payables stood at $4.0 million for Q4 2025, which was down 2161.74% from $5.4 million recorded in Q3 2025.
- In the past 5 years, Karyopharm Therapeutics' Payables registered a high of $9.0 million during Q1 2023, and its lowest value of $813000.0 during Q3 2022.
- In the last 5 years, Karyopharm Therapeutics' Payables had a median value of $2.9 million in 2021 and averaged $3.4 million.
- In the last 5 years, Karyopharm Therapeutics' Payables tumbled by 6397.75% in 2021 and then skyrocketed by 51325.56% in 2024.
- Quarter analysis of 5 years shows Karyopharm Therapeutics' Payables stood at $1.6 million in 2021, then surged by 72.99% to $2.8 million in 2022, then grew by 12.62% to $3.1 million in 2023, then soared by 63.53% to $5.1 million in 2024, then dropped by 21.62% to $4.0 million in 2025.
- Its last three reported values are $4.0 million in Q4 2025, $5.4 million for Q3 2025, and $2.6 million during Q2 2025.